drugset / Trial / NCT00003962
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 1
Completed
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have hematologic cancer at risk of relapse.
Timeline
- Start
- 1998-04
- Primary completion
- 2000-06
- Completion
- 2000-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |